Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, regulatory
TL;DR
Innate Pharma filed a routine 6-K report with the SEC on June 17, 2024.
AI Summary
Innate Pharma SA, a French biotechnology company, filed a Form 6-K on June 17, 2024. The filing is a report of a foreign private issuer and does not contain specific financial figures or operational updates in the provided text. It primarily serves as a notification to the SEC regarding its status and filing requirements.
Why It Matters
This filing indicates Innate Pharma is meeting its reporting obligations as a foreign private issuer with the SEC, which is standard procedure for companies with securities traded in the US.
Risk Assessment
Risk Level: low — This filing is a standard procedural report and does not contain new material information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (dollar_amount) — SEC File Number
- June 17, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public in its home country, files or makes public with a stock exchange, or distributes or makes public to its security holders.
What is the filing date of this specific 6-K report?
The filing date of this specific 6-K report is June 17, 2024.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file annual reports under Form 20-F?
Yes, the filing indicates that Innate Pharma SA files annual reports under cover of Form 20-F.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-17 06:02:07
Filing Documents
- a6k-iphx240617.htm (6-K) — 9KB
- exhibit991-240617.htm (EX-99.1) — 22KB
- 0001598599-24-000047.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date June 17, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive officer